Navigation Links
CSIRO deal to commercialize 'artificial gut'
Date:6/9/2009

CSIRO Food Futures National Research Flagship and Australian company Stadvis Pty Ltd have signed a worldwide license agreement to commercialise an automated instrument that accurately predicts glycemic index (GI) and resistant starch (RS) in food products.

The machine will provide the food industry with an accurate means of testing the functional properties and potential human health benefits of new foods that is much quicker and more cost-effective than the current in vivo (human) method.

The GI and RS Analyser is the first of its kind in the world. The prototype works by mimicking the human digestion process and was originally developed to test the properties of new grains being developed by the Flagship.

Dr Bruce Lee, Director of the Food Futures Flagship, said this commercialisation agreement will help address the growing global demand for foods with defined health benefits through low GI and higher fibre content particularly resistant starch.

"Its principal purpose is to help food manufacturers develop a wider range of healthy food products far more cheaply and quickly than possible previously. It can also be used to screen germplasm for functional grain attributes," Dr Lee said.

"With the growing problem of obesity, diabetes and cardiovascular disease in Australia and around the world, there is increasing demand for low GI and foods high in resistant starch. Consumers need greater access to products with appropriate health benefits, and we believe this new GI and RS predictor will help achieve that goal," he said.

CSIRO awarded the license to commercialise the machine following an open Expression of Interest announcement by the CSIRO. Stadvis Managing Director, Mr Phillip Clancy, said the new instrument will be a valuable addition to his company's portfolio.

"Stadvis is pleased to have won the opportunity to partner with CSIRO to bring this technology to market. The new device will be marketed to food manufacturing companies and laboratories around the world," he said.

Until now predicting GI involved feeding the test food to a number of human volunteers and taking regular blood samples over the following hours to monitor changing blood sugar levels. This new machine can replace this expensive and time consuming process in the development phase of products, leaving the standard in vivo (human) test to the final stage of food development and labelling procedures.

CSIRO initiated the National Research Flagships to provide science-based solutions in response to Australia's major research challenges and opportunities. The nine Flagships form multidisciplinary teams with industry and the research community to deliver impact and benefits for Australia.


'/>"/>

Contact: Owen Craig
Owen.Craig@csiro.au
61-294-908-201
CSIRO Australia
Source:Eurekalert  

Related biology news :

1. CSIRO enlisted to avert global wheat supply crisis
2. MSU technology that converts plant fibers to biofuel commercialized
3. Progress toward artificial tissue?
4. Non-wovens as scaffolds for artificial tissue
5. Development of an artificial simulator of the nervous system to do research into diseases
6. Red pandas reveal an unexpected (artificial) sweet tooth
7. Artificial cells, simple model for complex structure
8. TECNALIA uses artificial vision to improve recycling of electronic scrap metal
9. Biomedical researchers create artificial human bone marrow in a test tube
10. Scientists identify cell changes leading to impaired artificial kidney function
11. Evolved Machines Selected as a Prime Contractor for DARPA Program to Engineer an Artificial Olfaction System
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
CSIRO deal to commercialize 'artificial gut'
(Date:5/16/2016)... 2016   EyeLock LLC , a market leader ... of an IoT Center of Excellence in ... development of embedded iris biometric applications. EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA. EyeLock,s platform uses video technology to deliver a ...
(Date:5/9/2016)... 9, 2016 Elevay is currently ... expanding freedom for high net worth professionals seeking travel ... globally connected world, there is still no substitute for ... duplicate sealing your deal with a firm handshake. This ... taking advantage of citizenship via investment programs like those ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... MONICA, Calif. , June 23, 2016  The Prostate Cancer Foundation ... pioneer increasingly precise treatments and faster cures for prostate cancer. Members of the ... institutions across 15 countries. Read More About the Class ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report ... detail how a patient who developed lymphedema after being treated for breast cancer benefitted ... change the paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
Breaking Biology Technology: